Literature DB >> 2081183

Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors.

W R Osborne1, R A Hock, M Kaleko, A D Miller.   

Abstract

Three retroviral vectors, containing a human adenosine deaminase (ADA) cDNA linked to either the simian virus 40 (SV40) early promoter, the human cytomegalovirus (CMV) immediate early promoter, or the Moloney murine leukemia virus (MoMLV) promoter, were tested for their ability to express ADA following infection and transplantation of murine bone marrow. Virus was produced by using PA317 amphotropic retrovirus packaging cells. The titer of each of the vectors was similar and no helper virus was detected. Human ADA was expressed in the blood of some animals for 6 months after transplantation of infected marrow, and vector DNA was found in the spleen and in bone marrow from these animals. The percentage of animals expressing human ADA (33%) and the amount of human ADA in blood (1-5% of total ADA) was similar for each of the vectors. These results show that amphotropic vectors are capable of infecting pluripotent hematopoietic stem cells having long-term repopulating ability, and that a variety of promoters allow gene expression following differentiation of these early cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081183     DOI: 10.1089/hum.1990.1.1-31

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

1.  Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells.

Authors:  V W van Beusechem; A Kukler; P J Heidt; D Valerio
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 2.  Hematopoietic stem cell gene therapy:assessing the relevance of preclinical models.

Authors:  Andre Larochelle; Cynthia E Dunbar
Journal:  Semin Hematol       Date:  2013-04       Impact factor: 3.851

Review 3.  Retroviral vectors: from cancer viruses to therapeutic tools.

Authors:  A Dusty Miller
Journal:  Hum Gene Ther       Date:  2014-12       Impact factor: 5.695

4.  Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter.

Authors:  Sara M Fitzgerald; Rakesh K Goyal; William R A Osborne; Jennifer D Roy; John W Wilson; R E Ferrell
Journal:  Hum Genet       Date:  2006-01-31       Impact factor: 4.132

5.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

6.  The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction.

Authors:  D Orlic; L J Girard; C T Jordan; S M Anderson; A P Cline; D M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

7.  Protection against tuberculosis by bone marrow cells expressing mycobacterial hsp65.

Authors:  C L Silva; R L Pietro; A Januario; V L Bonato; V M Lima; M F da Silva; D B Lowrie
Journal:  Immunology       Date:  1995-12       Impact factor: 7.397

8.  Stable correction of maple syrup urine disease in cells from a Mennonite patient by retroviral-mediated gene transfer.

Authors:  H Koyata; R P Cox; D T Chuang
Journal:  Biochem J       Date:  1993-11-01       Impact factor: 3.857

9.  A proline-rich sequence unique to MEK1 and MEK2 is required for raf binding and regulates MEK function.

Authors:  A D Catling; H J Schaeffer; C W Reuter; G R Reddy; M J Weber
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

10.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.

Authors:  I Rivière; K Brose; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.